Dosage regimen for thrombopoietin receptor agonist
AssigneeJiangsu Hengrui Pharmaceuticals Co., Ltd.
InventorsHongda LIN, Kai SHEN, Yaqi SHEN, Yue HU, Yanhua DING
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a dosage regimen for a thrombopoietin receptor agonist. In particular, the present disclosure relates to a method of administering hetrombopag or a pharmaceutically acceptable salt thereof to a patient in need, the patient suffering from mild liver injury or moderate liver injury.
Claims20
A method for administering herombopag or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the patient has a mild hepatic impairment;
- the method comprises:
- administering to the patient having a mild hepatic impairment a therapeutically effective amount of herombopag or the pharmaceutically acceptable salt thereof, wherein an initial dose of the herombopag or the pharmaceutically acceptable salt thereof is unadjusted as compared to an initial dose administered to a patient having normal liver function.
A method for administering herombopag or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the patient has a moderate hepatic impairment;
- the method comprises:
- administering to the patient having a moderate hepatic impairment a therapeutically effective amount of herombopag or the pharmaceutically acceptable salt thereof, wherein an initial dose of the herombopag or the pharmaceutically acceptable salt thereof is less than an initial dose administered to a patient having normal liver function or a mild hepatic functional impairment.
A method for administering herombopag or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein administering a dose of the herombopag or the pharmaceutically acceptable salt thereof to a patient having a mild, moderate, or severe hepatic impairment results in higher exposure than administering the dose to a patient having normal liver function.
Dependencies are inferred from the claim text.